Phase I Trial of Cediranib in combination with cisplatin and pemetrexed in chemo naive patients with unresectable malignant pleural mesothelioma (SWOG S0905)

BACKGROUND: In malignant pleural mesothelioma (MPM), targeting angiogenesis, with cediranib, a vascular endothelial growth factor receptor (VEGFR) and platelet derived growth factor receptor (PDGFR) inhibitor, may have therapeutic potential. METHODS: S0905 phase I combined cediranib (2 dose cohorts...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:J Thorac Oncol
Autors principals: Tsao, Anne S., Moon, James, Wistuba, Ignacio I., Vogelzang, Nicholas J., Kalemkerian, Gregory P., Redman, Mary W., Gandara, David R., Kelly, Karen
Format: Artigo
Idioma:Inglês
Publicat: 2017
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5690479/
https://ncbi.nlm.nih.gov/pubmed/28599887
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.jtho.2017.05.021
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars